News Tarsus gets first FDA nod for mite blepharitis therapy A common eyelid disease caused by infestation with tiny parasitic mites that live in hair follicles now has its first approved treatment in the US.<
News UCB buys cell therapy biotech Candid for $2bn upfront Belgian biotech UCB has made its second acquisition of the year, buying T-cell engager player Candid Therapeutics for up to $2.2 billion.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.